<DOC>
	<DOC>NCT01481610</DOC>
	<brief_summary>The purpose of this study is to determine whether the use of lumiracoxib in this particular population is associated with a decrease in glomerular filtration rate (GFR) compared to diclofenac; and to compare the magnitude of such impairment, if any, associated with use of lumiracoxib and diclofenac.</brief_summary>
	<brief_title>Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<criteria>chronic joint pain, requiring analgesia preexisting chronic kidney injury, stage K/DOQI III (GFR 30 59 ml/min) in a stable phase of CKD (i.e. not AKI, not hospitalized) without contraindications for NSAID therapy who have signed an informed consent having received any NSAID 2 weeks prior to study start history of / actual PUD patients with ESRD (K/DOQI IV, V or replacement therapy) history of hypersensitivity or allergies to any of the treatments history of / actual GI bleeding with impaired liver function tests using ACEI / ARB</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Kidney Failure, Chronic</keyword>
	<keyword>Arthralgia</keyword>
	<keyword>NSAID</keyword>
	<keyword>Diclofenac</keyword>
	<keyword>Lumiracoxib</keyword>
	<keyword>Safety</keyword>
</DOC>